

Original article

# Prevalence of Vitamin B<sub>12</sub> Deficiency in Libyan Type 2 Diabetic Patients Treated with Metformin

Elmabruk Gamag\*, Waled Alsalmi

Department of Medical Laboratories, Faculty of Medical Technology, Sabratha University, Libya

## ARTICLE INFO

Corresponding Email. [Elmabruk.gamag@sabu.edu.ly](mailto:Elmabruk.gamag@sabu.edu.ly)

Received: 26-08-2024

Accepted: 22-10-2024

Published: 08-10-2024

**Keywords.** Diabetes Mellitus, Metformin, Vitamin B12.

**Copyright:** © 2024 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution International License (CC BY 4.0). <http://creativecommons.org/licenses/by/4.0/>

## ABSTRACT

Metformin is the most-used drug in type 2 diabetes mellitus management and its long-term use may consequent to vitamin B<sub>12</sub> deficiency. The lack of studies from Libya investigating the risk of association between these two presents a gap in our understanding of this issue. Our study aimed to estimate the prevalence of vitamin B<sub>12</sub> deficiency in metformin treated diabetic patients and non-metformin treated patients and its correlation with diabetic duration and gender. Specifically, we tested the hypothesis that T2DM patients treated with metformin exhibit a decrease in vitamin B<sub>12</sub> levels and are considered at risk for developing B<sub>12</sub> deficiency depending on the diabetic duration and metformin use. A total of 81 samples of metformin treated diabetic patients (N=58) and non-metformin diabetic treated patients (N=23) were collected and underwent assessment of F.B.S, HbA1c and B12 level. The total mean age was 46.4± 8.27 (47.25± 9.22 for males and 45.55± 7.32 for males respectively). Total mean and standard deviation of blood glucose level was 173.93± 29.87 mg/dl (158.25± 27.35 and 184.18± 27.06 for males and females, respectively). Total mean and standard deviation HbA1c level was 6.81± 1.98% (5.94± 1.31 and 7.37± 2.14 for males and females, respectively). Total mean and standard deviation of vitamin B12 level was 435.53 ± 251.31 (575.62 ± 250.21 and 342.76± 205.91 for males and females, respectively). Our study indicated that the shortage of vitamin B12 was generally found in our population, insufficient vitamin B12 level was frequently reported in metformin administration to patients with T2DM and could progress into deficiency. Further larger studies are required to assess vitamin B12 level in those patients.

**Cite this article.** Gamag E, Alsalmi W. Prevalence of Vitamin B12 Deficiency in Libyan Type 2 Diabetic Patients Treated with Metformin. *Alq J Med App Sci.* 2024;7(4):1072-1076. <https://doi.org/10.54361/ajmas.247422>

## INTRODUCTION

Diabetes mellitus is a primary public health concern with increasing prevalence and long-lasting complications. Despite the great advances in medical and diabetes sciences, it is still an incurable life-long disease leading to a major public panic, and swiftly growing among different age groups of both men and women [1]. The global prevalence of diabetes is expected at 7.5% (374 million) in 2019 and is projected to reach 8.0% (454 million) by 2030, and the number of people with diabetes is expected to reach to 693 million by 2045 [2]. More importantly, it is reported that Libya has the highest prevalence in North Africa and among Arabic nations, in a study included 4000 individuals, 73% of the

individuals are diabetic or at high risk to have diabetes [3]. Diabetes has been classified into two fundamental categories: insulin-dependent diabetes mellitus (T1DM), and non- insulin-dependent diabetes mellitus (T2DM)[2].

Metformin is the most commonly prescribed oral anti-diabetic drug in patients with T2DM[4]. Metformin, which belongs to biguanide group of drugs has been the treatment of choice of non- insulin-dependent diabetes mellitus [1]. However, long-term usage of metformin is a known pharmacological cause of Vitamin B<sub>12</sub> deficiency[4]. The mechanism by which metformin causes vitamin B<sub>12</sub> deficiency has not been clearly understood; however, changes in small bowel motility as a result of hypocalcemia that leads to enhancement of bacterial overgrowth with substantial vitamin B<sub>12</sub> deficiency and suppression of vitamin B<sub>12</sub> absorption are proposed mechanisms [5].

Increasing evidences shown a strong correlation between prolonged usage of metformin and vitamin B<sub>12</sub> deficiency. It may affect the calcium dependent absorption of vitamin B<sub>12</sub>, the serum vitamin B<sub>12</sub> values was showed to be inversely related to the dose and duration of metformin usage [1]. The diagnostic criteria for vitamin B<sub>12</sub> deficiency are based on a decreased serum concentration of vitamin B<sub>12</sub> combined with hematological and/or clinical signs of vitamin B<sub>12</sub> deficiency [6]. Furthermore, measurements of metabolites such as methylmalonic acid and homocysteine have been shown to be more sensitive in the diagnosis of vitamin B<sub>12</sub> deficiency than measurement of serum B<sub>12</sub> levels alone [7]. The association of metformin with vitamin B<sub>12</sub> deficiency has been widely studied, its duration of use and dose of metformin have also been shown to influence vitamin B<sub>12</sub> levels. While some clinical studies showed that metformin is a leading cause of decreased vitamin B<sub>12</sub> levels, other studies did not find this to be significant. A meta-analysis of six randomized controlled trials showed a crucial decrease in vitamin B<sub>12</sub> levels stimulated by metformin and recommended that this may be dose dependent [8]. Another published study reported that Korean patients on higher doses (metformin >1g daily) and with longer treatment duration (>4 years) were more likely to exhibit a reduction in vitamin B<sub>12</sub> levels[9]. However, no crucial correlation between serum B<sub>12</sub> level among patients treated with metformin in different doses was recently reported [10].

The high incidence of DM and elevated morbidity rate of vitamin B<sub>12</sub> deficiency with metformin use, which has been reported in several studies worldwide, in addition to the lack of studies from Libya investigating the association between these two presents a gap in our understanding of this issue. Therefore, we aimed to estimate the prevalence of vitamin B<sub>12</sub> deficiency in metformin-treated T2DM patients and non-metformin treated patients and its association with diabetic duration and gender. Specifically, we tested the hypothesis that T2DM patients treated with metformin will exhibit a decrease in vitamin B<sub>12</sub> levels and are considered at risk for developing B<sub>12</sub> deficiency depending on the diabetic duration and metformin use.

## **METHODS**

### ***Study design***

A cross sectional study was conducted in western Libya particularly in Sabrathra and Surrman provinces to estimate the prevalence of vitamin B<sub>12</sub> deficiency in metformin-treated T2DM patients and non-metformin treated patients.

### ***Data collection***

Data were collected from private laboratories in the city of Sabratha and Surman-Libya. A total of 81 samples of T2DM patients who visited Alweqaia laboratory in Sabratha and Central laboratory in Surman between February and July were included in our study. Questionnaires were completed and participants with T2DM treated with metformin as well as those not on metformin treatment underwent assessment of FBS, HbA<sub>1c</sub> and B<sub>12</sub> level.

### ***Ethical consideration***


This work was established according to medical research ethics, patients were informed about the study and agreed to participate.

### ***Statistical analysis***

The results were analyzed using SPSS software package version 20 to apply one way ANOVA test to find out the statistical significance between variables. All results were considered to be significant at p value < 0.01.

## **RESULTS**

In the present study 81 type 2 diabetes mellitus patients were included for both sexes (32 males and 49 females) (Figure1).



*Figure 1. The total numbers of males and females*

Out of 92 sample size 81 subjects were recruited of whom 23 were not on metformin supplementation and 58 were on metformin supplementation. The total mean age was  $45.68 \pm 7.80$  for metformin taken patients and  $47.56 \pm 8.89$  for patients not on metformin. Vitamin B<sub>12</sub> in patients on metformin was  $377.20 \pm 219.74$  whereas those not on metformin vitamin B<sub>12</sub> level was  $582.60 \pm 270.12$  (Table 1).

*Table 1. Distribution of biochemical parameters (blood glucose, HbA1c and vitamin B12) in accordance to metformin intake.*

Parameters	Metformin taken N= 58	Metformin non taken N= 23	P. Value
Age	$45.68 \pm 7.80$	$47.56 \pm 8.89$	0.3
Duration of diabetes	$9.60 \pm 5.29$	$4.82 \pm 2.60$	< 0.01
Blood glucose levels mg/dl	$181.10 \pm 30.46$	$155.86 \pm 19.07$	< 0.01
HbA1c %	$6.92 \pm 1.90$	$6.51 \pm 2.17$	0.40
Vitamin B12	$377.20 \pm 219.74$	$582.60 \pm 270.12$	< 0.01

The present study shows total means and standard deviations of biochemical parameters of blood glucose, HbA1c and vitamin B<sub>12</sub>. Total mean age was  $46.4 \pm 8.27$  ( $47.25 \pm 9.22$  for males and  $45.55 \pm 7.32$  for females, respectively). Total mean and standard deviation of blood glucose level was  $173.93 \pm 29.87$  mg/dl ( $158.25 \pm 27.35$  and  $184.18 \pm 27.06$  for males and females, respectively). Total mean and standard deviation HbA1c level was  $6.81 \pm 1.98\%$  ( $5.94 \pm 1.31$  and  $7.37 \pm 2.14$  for males and females, respectively). Total mean and standard deviation of vitamin B<sub>12</sub> level was  $435.53 \pm 251.31$  ( $575.62 \pm 250.21$  and  $342.76 \pm 205.91$  for males and females, respectively) (Table 2).

*Table 2. The means and standard deviations of biochemical parameters (blood glucose, HbA1c and vitamin B12) in males and females.*

Parameters	Total mean and standard deviation	Male Mean $\pm$ SD	Female Mean $\pm$ SD	P. Value
Age (years)	$46.4 \pm 8.27$	$47.25 \pm 9.22$	$45.55 \pm 7.32$	0.84
Blood glucose mg/dl	$173.93 \pm 29.87$	$158.25 \pm 27.35$	$184.18 \pm 27.06$	< 0.01
HbA1c %	$6.81 \pm 1.98$	$5.94 \pm 1.31$	$7.37 \pm 2.14$	< 0.01
Vitamin B12	$435.53 \pm 251.31$	$575.62 \pm 250.21$	$342.76 \pm 205.91$	< 0.01

Our results also revealed to the distribution of blood glucose, HbA1c and vitamin B<sub>12</sub> levels in accordance to the duration of diabetes (< 5 years, 5-10 years and > 10 years). Mean blood glucose levels were  $147.18 \pm 15.28$ ,  $177.25 \pm 15.42$  and  $197.37 \pm 30.80$  (< 5 years, 5-10 years and > 10 years, respectively). Mean HbA1c levels was  $5.25 \pm 0.75$ ,  $7.43 \pm 1.90$  and  $7.74 \pm 2.02$  (< 5 years, 5-10 years and > 10 years, respectively). Mean vitamin B<sub>12</sub> levels was  $711.85 \pm 239.64$ ,  $371.85 \pm 54.91$  and  $222.88 \pm 58.53$  (< 5 years, 5-10 years and > 10 years, respectively) (Table 3).

**Table 3. Distribution of biochemical parameters (blood glucose, HbA1c and vitamin B12) in accordance to the duration of diabetes mellitus.**

Parameters	Duration of diabetes mellitus			P value
	< 5 years N = 27 2.66 ± 1.07	5-10 years N = 27 7.59 ± 1.47	> 10 years N = 27 14.48 ± 2.25	
Blood glucose levels mg/dl	147.18 ±15.28	177.25 ±15.42	197.37 ±30.80	< 0.01
HbA1c %	5.25 ±0.75	7.43 ±1.90	7.74 ±2.02	< 0.01
Vitamin B12	711.85 ±239.64	371.85 ±54.91	222.88 ±58.53	< 0.01

## DISCUSSION

In our study we observed a significant correlation between metformin administration and vitamin B<sub>12</sub> insufficiency. Patients treated with metformin exhibit significantly lower B<sub>12</sub> level (377.20) than non-metformin treated patients (582.60) with p value <0.01. These findings were consistent with a previously published data in which a remarkable decrease in vitamin B<sub>12</sub> level with metformin treated patients was reported. One of these studies showed a crucially increased prevalence of vitamin B<sub>12</sub> deficiency in patients with T2DM treated with metformin [8]. A recent study also reported a decreased vitamin B<sub>12</sub> level and an increased risk of vitamin B<sub>12</sub> deficiency with metformin intake to patients with T2DM [2]. Long term duration and accumulative dose of metformin significantly increases the risk of vitamin B<sub>12</sub> deficiency [11]. On the other hand, no crucial correlation between serum B<sub>12</sub> level among patients treated with metformin in different doses was recently reported [10].

In the present study, a normal vitamin B<sub>12</sub> concentration (more than 220pg/ml) in both male and female was identified despite the remarkable difference in vitamin B<sub>12</sub> concentration between genders. Females exhibit a decreases vitamin B<sub>12</sub> level (342.76) compared to males B<sub>12</sub> level (575.62) with P value <0.01. These results were concur with a recent study which showed a higher prevalence of vitamin B<sub>12</sub> deficiency in woman [11]. In addition, a previous study conducted in the city of Benghazi showed a noticeably lower vitamin B<sub>12</sub> level in females than males [12]. However, these findings were different to other study in which female patients found to have higher levels of vitamin B<sub>12</sub> compared to male[13]. Most studies do not describe the differences between vitamin B<sub>12</sub> levels according to gender and no physiological explanation was indicated for these results. Our study did not demonstrate any noticeable correlation between vitamin B<sub>12</sub> levels and age.

Our study demonstrated that the risk of cobalamin deficiency is correlated with an increase in diabetic duration with P value <0.01. Patients with diabetes longer than ten years exhibit a significant lower B<sub>12</sub> levels (222.88) in comparison to those less than 5 years diabetic patients (711.85). Moreover, patients with diabetes 5-10 years duration showed a decrease vitamin B<sub>12</sub> level (371.85). Our findings clearly showed that a potential vitamin B<sub>12</sub>deficiency increases with long term diabetic duration, these finding were consistent with a study which demonstrated that the risk of developing vitamin B<sub>12</sub> deficiency is correlated with an increase in diabetic duration [10].

Several factors are contributed to vitamin B<sub>12</sub> deficiency including insufficient nutrition and acquired or inherited defects which disrupt B<sub>12</sub> absorption and processing pathway. It has been widely explained that the interference by metformin on calcium dependent membrane action responsible for vitamin B<sub>12</sub>intrinsic factor absorption in the terminal ileum[8]. Additionally, vitamin B<sub>12</sub> malabsorption alterations, alterations of the motility of small intestinal with consequent bacterial overgrowth, or effects on inhibition of vitamin B<sub>12</sub> intrinsic factor secretion are participates in metformin induced B<sub>12</sub> deficiency [13].

## CONCLUSION

This study indicated that the shortage of vitamin B<sub>12</sub> was generally found in our population, insufficient vitamin B<sub>12</sub> level was frequently reported in metformin administration to patients with T2DM and could progress into deficiency. vitamin B<sub>12</sub> deficiency is influenced by the occurrence and duration of diabetes. Routine monitoring for vitamin B<sub>12</sub> serum levels is needed to patients with T2DM, prolonged T2DM duration. Further studies are needed to assess the correlation between metformin duration and dose.

**Conflict of interest.** Nil

## REFERENCES

1. Khan A, Shafiq I, Shah MH. Prevalence of vitamin B12 deficiency in patients with type II diabetes mellitus on metformin: a study from Khyber Pakhtunkhwa. *Cureus*. 2017;9(8).
2. Alhaji JH. Vitamin B12 Deficiency in Patients with Diabetes on Metformin: Arab Countries. *Nutrients*. 2022;14(10):2046.
3. Eltobgi A, editor Libya has the highest prevalence of diabetes mellitus type 2 in North Africa and in the Arab world. *Endocrine Abstracts*; 2009: Bioscientifica.
4. Farooq MD, Tak FA, Ara F, Rashid S, Mir IA. Vitamin B12 Deficiency and Clinical Neuropathy with Metformin Use in Type 2 Diabetes. *Journal of Xenobiotics*. 2022;12(2):122-30.
5. Selhub J. Public health significance of elevated homocysteine. *Food and nutrition bulletin*. 2008;29(2\_suppl1):S116-S25.
6. Aparicio-Ugarriza R, Palacios G, Alder M, González-Gross M. A review of the cut-off points for the diagnosis of vitamin B12 deficiency in the general population. *Clinical Chemistry and Laboratory Medicine (CCLM)*. 2015;53(8):1149-59.
7. Oh RC, Brown DL. Vitamin B12 deficiency. *American family physician*. 2003;67(5):979-86.
8. Miyan Z, Waris N. Association of vitamin B12 deficiency in people with type 2 diabetes on metformin and without metformin: a multicenter study, Karachi, Pakistan. *BMJ Open Diabetes Research and Care*. 2020;8(1):e001151.
9. Krishnan GD, Zakaria MH, Yahaya N. Prevalence of vitamin b12 deficiency and its associated factors among patients with type 2 diabetes mellitus on metformin from a district in Malaysia. *Journal of the ASEAN Federation of Endocrine Societies*. 2020;35(2):163.
10. Almatrafi SB, Bakr E-SH, Almatrafi AA, Altayeb MM. Prevalence of vitamin B12 deficiency and its association with metformin-treated type 2 diabetic patients: A cross sectional study. *Human Nutrition & Metabolism*. 2022;27:200138.
11. Alharbi TJ, Tourkmani AM, Abdelhay O, Alkhashan HI, Al-Asmari AK, Bin Rsheed AM, et al. The association of metformin use with vitamin B12 deficiency and peripheral neuropathy in Saudi individuals with type 2 diabetes mellitus. *PLoS one*. 2018;13(10):e0204420.
12. Elsaier A, Elamami A, Zaid I. Vitamin B12 deficiency in patients with type 2 diabetes on metformin therapy. *Ibnosina Journal of Medicine and Biomedical Sciences*. 2017;9(03):72-5.
13. Alvarez M, Sierra OR, Saavedra G, Moreno S. Vitamin B12 deficiency and diabetic neuropathy in patients taking metformin: a cross-sectional study. *Endocrine connections*. 2019;8(10):1324-9.

## مدى انتشار نقص فيتامين ب 12 لدى مرضى السكري من النوع الثاني الذين يعالجون بالميتفورمين

المبروك غمق\*, وليد السالمي

قسم المختبرات الطبية، كلية التقنية الطبية، جامعة صبراتة، ليبيا

### المستخلص

يعتبر الميتفورمين من أكثر الأدوية استخداماً في علاج مرض السكري من النوع الثاني لكن استخدامه على المدى الطويل قد يؤدي إلى نقص فيتامين ب 12. إن عدم وجود دراسات من ليبيا تبحث في خطر الارتباط بين هذين الأمرين يمثل فجوة في فهمنا لهذه الموضوع. هدفت دراستنا إلى تقدير مدى انتشار نقص فيتامين ب 12 لدى مرضى السكري المعالجين بالميتفورمين والمرضى غير المعالجين بالميتفورمين وارتباطه بمدى الإصابة بالسكري والجنس. على وجه التحديد، قمنا باختبار الفرضية القائلة بأن مرضى السكري الذين عولجوا بالميتفورمين يظهرون انخفاضاً في مستويات فيتامين ب 12 ويعتبرون معرضين لخطر الإصابة بنقص ب 12 اعتماداً على مدة الإصابة بالسكري واستخدام الميتفورمين. تم جمع 81 عينة من مرضى السكري منهم 58 يعالجون بالميتفورمين و 23 عسنة لايعالجون بالميتفورمين. بلغ متوسط العمر الإجمالي  $8.27 \pm 46.4$  (للذكور  $9.22 \pm 47.25$  وللإناث  $7.32 \pm 45.55$  على التوالي). كان المتوسط الإجمالي والانحراف المعياري لمستوى الجلوكوز في الدم  $29.87 \pm 173.93$  ملغم / ديسيلتر ( $158.25 \pm 27.35$  و  $27.06 \pm 184.18$  للذكور والإناث على التوالي). كما أن المتوسط الإجمالي والانحراف المعياري لمستوى HbA1c كان  $6.81$  (للذكور  $2.14 \pm 7.37$  وللإناث  $1.98 \pm 5.94$  على التوالي). كما أن المتوسط الإجمالي والانحراف المعياري لمستوى فيتامين ب 12  $251.31 \pm 435.53$  (للذكور  $250.21 \pm 575.62$  وللإناث  $205.91 \pm 342.76$  على التوالي). أشارت دراستنا إلى أن النقص في فيتامين ب 12 موجود بشكل عام في مجتمعنا، وقد تم الإبلاغ عن عدم كفاية مستوى فيتامين ب 12 بشكل متكرر عند تناول الميتفورمين للمرضى الذين يعانون من السكري ويمكن أن يتطور إلى نقص حاد.

**الكلمات الدالة:** مرض السكري، الميتفورمين، فيتامين ب 12.